CCNB1 and cancer: Because the treatment with beta-carboline derivatives leads to accumulation of cancer cells at G2/M stage, wherein the degradation of cyclin B1 is prohibited, the cell cycle arrest induced by high concentration of DH166 may cause elevated cyclin B1.